Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F - Wikidata - awgldk - TriplyDB

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

http://www.wikidata.org/entity/Q37232941

about

The role of small adaptor proteins in the control of oncogenic signalingr driven by tyrosine kinases in human cancer Genetics of myeloproliferative neoplasms Stem and progenitor cell subsets are affected by JAK2 signaling and can be monitored by flow cytometry.Lnk constrains myeloproliferative diseases in mice.Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis.JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.LNK (SH2B3): paradoxical effects in ovarian cancer.Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3.Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.A nonsynonymous LNK polymorphism associated with idiopathic erythrocytosis JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms Genetic loss of SH2B3 in acute lymphoblastic leukemia.Erythropoietin receptor response circuits A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.The Lnk adaptor protein: a key regulator of normal and pathological hematopoiesis.Role of the adaptor protein LNK in normal and malignant hematopoiesis.Molecular biology of Philadelphia-negative myeloproliferative neoplasms Genetic and epigenetic alterations of myeloproliferative disorders.Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia.LNK mutations and myeloproliferative disorders.The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms.Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.Isogenic Cellular Systems Model the Impact of Genetic Risk Variants in the Pathogenesis of Type 1 Diabetes.Selective Interference Targeting of Lnk in Umbilical Cord-Derived Late Endothelial Progenitor Cells Improves Vascular Repair, Following Hind Limb Ischemic Injury, via Regulation of JAK2/STAT3 Signaling.SH2B proteins bind JAK2 Cytosolic lysine residues enhance anterograde transport and activation of the erythropoietin receptor.Application of a Genetic Risk Score to Racially Diverse Type 1 Diabetes Populations Demonstrates the Need for Diversity in Risk-Modeling.Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up?Cytokine Receptors

P2860

Q26770682-E8EAF997-EDC3-4802-9947-F7B02B7AF003 Q26823651-28658214-DC38-4C54-B8C0-1B566002702A Q31156217-02EE20F6-DDA4-43FF-9774-1A57CF8A4A19 Q33882944-415C2425-6770-428F-9224-AFEEC4898D4C Q33997280-556F1840-3AF4-47ED-936A-2D554F3BD1F8 Q34150008-05A4A883-5F0F-40C3-942B-38F10C65954A Q34166859-D290603C-73BA-42A6-B089-FD08D5A1CAFF Q34302585-3A5659C9-D41E-4BCF-B5E9-E2865460A023 Q34629928-62730E93-FAF2-4752-A165-F165DA366883 Q36005362-AAB7F6F0-2D02-4DE1-9A8C-99AD4F8B715E Q36261941-0D6B4F17-5CF7-4667-A9A6-862220D0CDF5 Q36333540-F3868C32-1E57-479A-ADE9-019F1A06B527 Q36352535-C86FFAC0-7BBB-41BF-A562-F76E3A7DF91C Q36901651-25B5761A-7239-479F-AA2B-6BE202E84FC5 Q36907588-AC29AE84-9B96-48D0-A3B8-9C9CF5793AA6 Q37168138-986B8060-E29C-44D5-953E-E97525850B46 Q37215146-7A49CFD0-B603-462D-82CF-E264A97E415C Q37696206-DC93F12F-2156-49D1-B68C-48D67920B6AD Q37921836-B13A6F84-2D79-44EF-B2DF-D3F0D92F8C09 Q38044625-394AE9C7-97F8-4F4F-B626-2D7A7B339E2D Q38050407-556ACB04-4917-4606-89D6-E47B89D4A2FD Q38050756-1D74DF58-103D-4B76-87A3-291539679221 Q38066786-28ABB9B9-C1AE-456D-AA50-F9F96785BDA5 Q38102578-23E756B6-EFC7-455E-931B-65E052B3F590 Q38667486-3465D7E7-B650-4DD2-ACDF-23A3053C238A Q39292396-148A17D0-1777-4B90-88E0-5B296564C4EA Q39788785-8B1B5CE6-99FB-4E22-88C0-2194E1476C28 Q42870230-ACBABA89-5EB2-4604-A871-77B18E53960C Q42931701-7780AC1C-252C-4B75-BBF9-739A7B16AF7F Q45818945-3D967CA9-A8FF-41E7-BB87-FBBCF5E8D7D2 Q48146328-B8FC7649-9FD0-465A-9A19-16D9B0674964 Q50291343-3A13BE57-9832-4711-B424-4E68E9D29934 Q51889679-F822C0D9-5660-4182-B23D-2B78EA364037 Q52655332-BA49608B-AE67-42C6-BC6A-92F14BDE6D10 Q54574818-741C6667-92D4-4586-A19D-F2904E492208 Q57252653-36DB7947-83B8-444E-8762-BA6DD6181CFD

P2860

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

http://www.wikidata.org/entity/Q37232941

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

@en

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.

@nl

type

label

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

@en

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.

@nl

prefLabel

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

@en

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.

@nl

P1433

Q37232941-8913E1EE-BF4B-42D8-91CF-429C2865CB89

P1476

Q37232941-B2CD09D9-92FF-4C85-A162-11FC1DB0EAEC

P2093

Q37232941-5751650C-53D4-4B4F-99B1-AB22C2D4ECB7

Q37232941-73F3864F-CC32-40B1-BC05-62478052DCA5

Q37232941-BCD96034-4311-4BAB-855B-7F206DF31628

Q37232941-C754E81C-4EB5-46AA-B2EF-FB94FB8C13CD

Q37232941-EA27AC61-ED9F-4A36-A853-6B924D45C4C9

P2860

Q37232941-05751601-49DA-4D98-82DC-FDE9763928FE

Q37232941-0741C99E-B612-40EA-9219-74CDB925065F

Q37232941-084FC9D8-EBF4-4CA3-AC56-E395933825B2

Q37232941-0BB9EE03-B2F9-4AAD-80AE-03AE467E6655

Q37232941-0CAC9435-4ED1-4BFB-B6E4-2BC3B1DA99CE

Q37232941-14B865A0-75D3-4133-8F55-5A6A622DC47B

Q37232941-1A23EFF6-35A2-4737-A8A8-36D7B207F7C4

Q37232941-23993AF7-B1E6-4DB5-AE86-E419BD273931

Q37232941-2AE13E37-CBBB-48CD-9F9D-AAB7EB659170

Q37232941-2B8371C7-0AFA-41A2-9AD7-F38872499FE4

P304

Q37232941-D233477D-8808-4C34-87AD-B6F47BF40DF2

P31

Q37232941-6A2B361C-7650-46D0-9F94-16B48228F23B

P356

Q37232941-F97DCDA3-0D14-44F8-A638-82FD177FF911

P433

Q37232941-82DC5462-04F7-458F-8759-81D91E3C0310

P478

Q37232941-EDC4C32B-080E-41A9-83D6-E33943021ACA

P50

Q37232941-A84EB11D-7009-4661-B069-8979EB1CF80A

P577

Q37232941-F2B47778-DF2D-416E-9A88-04C584AE5447

P5875

Q37232941-4FB2E092-0832-4DDA-966F-5C129215BE7D

P698

Q37232941-72A1E9FD-36ED-423C-8179-D4D3080AF6BF

P932

Q37232941-02C505E6-7FF0-49E8-BD88-7F9C59DD2B58

P356

P1433

Journal of Leukocyte Biology

P1476

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

@en

P2093

H Phillip Koeffler

http://www.w3.org/2001/XMLSchema#string

Hongtao Xing

http://www.w3.org/2001/XMLSchema#string

Qi Cao

http://www.w3.org/2001/XMLSchema#string

Saskia Gueller

http://www.w3.org/2001/XMLSchema#string

Sigal Gery

http://www.w3.org/2001/XMLSchema#string

P2860

APS, an adaptor protein containing PH and SH2 domains, is associated with the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis

APS, an adaptor protein containing Pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl

Structural characterization of a novel Cbl phosphotyrosine recognition motif in the APS family of adapter proteins

Kinase activation through dimerization by human SH2-B

The adapter protein APS associates with the multifunctional docking sites Tyr-568 and Tyr-936 in c-Kit

Differential binding to and regulation of JAK2 by the SH2 domain and N-terminal region of SH2-bbeta

Identification of SH2-Bbeta as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling

Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk

Structural basis for recruitment of the adaptor protein APS to the activated insulin receptor

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

P304

957-965

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1189/JLB.0908575

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24207528

http://www.w3.org/2001/XMLSchema#string

P698

19293402

http://www.w3.org/2001/XMLSchema#string

P932

2698587

http://www.w3.org/2001/XMLSchema#string